secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2026-08-13T12:15:15+00:00
Accession:  0001193125-26-347957
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Q2 net loss $38.9M; BLA for prostate cancer drug planned Q4 2026
-----------------------------------------------------------------------

- Net loss $38.9M in Q2 2026 vs $4.8M in Q2 2025, including $12.2M net other expense from warrant liabilities.
- R&D expenses $19.8M (vs $7.0M YoY); G&A $6.9M (vs $4.2M YoY).
- Cash and equivalents $201.6M as of June 30, 2026; expected to fund operations into Q1 2028.
- BLA submission for aglatimagene in localized prostate cancer planned Q4 2026; potential U.S. launch in 2027 if approved.
- Phase 3 data in The Lancet Oncology showed 39% improvement in PCa-specific DFS at 58 months; Mark Sims appointed CCO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/0001193125-26-347957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-347957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer